Gene Editing · global
One Gene Edit, Three Years of Lipid Lowering: Monkey Study Tracks ANGPTL3 Therapy
After ten monkeys received a single base-editing infusion, triglycerides fell by an average of 43% over three years. The long-term follow-up adds evidence of durability for a one-time lipid-lowering therapy, while highlighting safety questions that must be answered as it moves into humans.
Controlling blood lipids often requires long-term medication. If a single treatment could enable the liver to keep producing less of a protein that raises blood lipid levels, the approach to treatment could change. A study published in Nature extended animal follow-up of this concept to three years: monkeys that received a single CRISPR base-editing infusion maintained triglyceride levels below their pretreatment levels. However, this remains preclinical evidence and cannot yet establish that patients would experience equally durable and safe effects.
The long-term follow-up included ten monkeys whose blood lipid levels were initially normal. Calculated as time-weighted averages across measurements over three years, blood ANGPTL3 protein levels fell by 94%, triglycerides by 43%, and low-density lipoprotein cholesterol (LDL-C) by 13%. These figures describe average changes over the entire follow-up period, rather than the results of a single blood draw in the third year. Liver samples also showed broadly comparable levels of editing at seven weeks and three years after dosing.
The therapy targets ANGPTL3, a protein secreted by the liver that inhibits certain enzymes involved in lipid breakdown. The researchers packaged messenger RNA encoding the ABE8.8 adenine base editor together with guide RNA into lipid nanoparticles for delivery into liver cells. By rewriting one DNA letter at the target site, the editor disrupts ANGPTL3 protein production. This design does not require first cutting both strands of DNA. The delivery materials and RNA are gradually cleared, while the resulting genetic change is expected to continue exerting its effect.
How the editing tools reach the liver is another key aspect of the study. Conventional lipid nanoparticles often depend heavily on LDL receptors to enter liver cells, but receptor function is very weak in some patients with severe inherited hypercholesterolemia. The team therefore added GalNAc sugar molecules to the particle surface, allowing entry through another receptor on liver cells and reducing dependence on LDL receptors.
This delivery design was tested in a separate experiment: in four monkeys whose LDL receptor gene had been disrupted, mean LDL-C fell from 458 milligrams per deciliter to 247 milligrams per deciliter by day 35 after treatment, a reduction of approximately 46%. Scienmag also summarized lipid-lowering results from other animal models of hyperlipidemia in the same paper. However, those experiments involved different animals from the monkeys with normal blood lipid levels followed for three years. The larger reductions cannot be directly applied to the long-term study, much less regarded as proven efficacy in patients with severe hyperlipidemia.
Regarding safety, the study observed transient elevations in liver enzymes in the monkeys, which returned to baseline within approximately two weeks. Subsequent examinations and tissue analyses found no persistent liver toxicity. In primary human liver cells, the researchers examined 3,096 candidate sites and detected no guide RNA–related off-target editing. However, testing candidate sites cannot cover every possible unintended change, and three years of follow-up in ten animals is insufficient to rule out rare risks or those that emerge later.
These results form the preclinical foundation for VERVE-201, whose human version is being evaluated in a phase 1b trial in patients with poorly controlled blood lipid levels. The research was funded by Verve Therapeutics, and several authors are employed by the company or have related financial interests. Beyond confirming the magnitude and durability of lipid lowering, human trials must clarify the long-term consequences of permanent editing. Whether it can reduce cardiovascular events such as heart attacks remains unanswered by this animal study.